Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$476,591
+$120,719 QoQ
Shares Held
18,530
-0.0% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#150
of 290 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 14%
Shared 0%
None 86%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARTINGALE ASSET MANAGEMENT L P holds $144,833,314 across 62 Biotechnology names. DNLI ranks #44 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
42,729 | $21,224,776 | |
| 2 | INCY |
Incyte Corp
|
168,818 | $19,137,208 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
59,492 | $14,335,787 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
18,953 | $11,817,953 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
17,562 | $5,551,172 | |
| 6 | ACAD |
Acadia Pharmaceuticals Inc
|
167,893 | $4,247,692 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
13,634 | $4,104,243 | |
| 8 | INVA |
Innoviva, Inc.
|
165,115 | $3,749,761 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $476,591 | 18,530 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $355,872 | 18,535 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $306,012 | 18,535 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||